Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation
ChiCTR2200062156Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in Delayed platelet engraftment (DPE), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Overall response rate at week 4. Started Jul 2022; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
Delayed platelet engraftment (DPE)
Beyond the preview
Go deeper on ChiCTR2200062156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062156.